Medicinal Chemistry strategies for PET tracer discovery

Hargreaves, 2008, The role of molecular imaging in drug discovery and development, Clin Pharmacol Ther, 83, 349, 10.1038/sj.clpt.6100467 Vallabhajosula, 2011, A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new, Semin Nucl Med, 41, 246, 10.1053/j.semnuclmed.2011.02.003 Salloway, 2014, Two phase III trials of bapineuzumab in mild-to-moderate Alzheimer’s disease, N Engl J Med, 370, 322, 10.1056/NEJMoa1304839 Laruelle, 2003, Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography, Mol Imaging Biol, 5, 363, 10.1016/j.mibio.2003.09.009 Pike, 2009, PET radiotracers: crossing the blood-brain barrier and surviving metabolism, Trends Pharmacol Sci, 30, 431, 10.1016/j.tips.2009.05.005 Piel, 2014, Positron emission tomography in CNS drug discovery and drug monitoring, J Med Chem, 57, 9232, 10.1021/jm5001858 Ariza, 2015, Tau positron emission tomography (PET) imaging: past, present, and future, J Med Chem, 58, 4365, 10.1021/jm5017544 Serdons, 2009, Developing new molecular imaging probes for PET, Methods, 48, 104, 10.1016/j.ymeth.2009.03.010 Roeda, 2010, Aliphatic nucleophilic radiofluorination, Curr Radiopharm, 3, 81, 10.2174/1874471011003020081 Preshlock, 2016, 18F-Labeling of arenes and heteroarenes for applications in positron emission tomography, Chem Rev, 116, 719, 10.1021/acs.chemrev.5b00493 Kealey, 2014, Transition metal mediated [11C]carbonylation reactions: recent advances and applications, J Label Compd Radiopharm, 57, 195, 10.1002/jlcr.3150 Antoni, 2015, Development of carbon-11 labelled PET tracers—radiochemical and technological challenges in a historic perspective, J Label Compd Radiopharm, 58, 65, 10.1002/jlcr.3258 Rotstein, 2016, 11CO bonds made easily for positron emission tomography radiopharmaceuticals, Chem Soc Rev, 45, 4708, 10.1039/C6CS00310A Harada, 2016, 18F-THK-5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer’s disease, J Nucl Med, 57, 208, 10.2967/jnumed.115.164848 Wang, 2014, In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs, J Med Chem, 19, 7999, 10.1021/jm500872p He, 2017, 1-(4-[18F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: a novel suitable radioligand with low lipophilicity for imaging σ1 receptors in the brain, J Med Chem, 60, 4161, 10.1021/acs.jmedchem.6b01723 Fujinaga, 2017, Development of a 18F-labeled radiotracer with improved brain kinetics for positron emission tomography imaging of translocator protein (18kDa) in ischemic brain and glioma, J Med Chem, 60, 4047, 10.1021/acs.jmedchem.7b00374 Prabhakaran, 2017, Radiosynthesis and in vivo evaluation of [11C]​A1070722, a high affinity GSK-​3 PET tracer in primate brain, ACS Chem Neurosci, 8, 1697, 10.1021/acschemneuro.6b00376 Schmidt, 2017, The value of PET ligand discovery to CNS drug development, Future Med Chem, 9, 351, 10.4155/fmc-2017-0018 Andrés, 2011, Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positrón emission tomography imaging, J Med Chem, 54, 5820, 10.1021/jm200536d Van Laere, 2013, Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain, J Nucl Med, 54, 1285, 10.2967/jnumed.112.118679 Andrés, 2012, Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging, J Med Chem, 55, 8685, 10.1021/jm300912k Lipinski, 2016, Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions, Adv Drug Delivery Rev, 101, 34, 10.1016/j.addr.2016.04.029 Guo, 2009, A biomathematical modeling approach to central nervous system radioligand discovery and development, J Nucl Med, 50, 1715, 10.2967/jnumed.109.063800 Wager, 2010, Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS-MPO) approach to enable alignment of druglike properties, ACS Chem Neurosci, 1, 435, 10.1021/cn100008c Zhang, 2013, Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand, J Med Chem, 56, 4568, 10.1021/jm400312y Naganawa, 2016, First in human assessment of the novel PDE2A PET radiotracer 18F-PF-05270430, J Nucl Med, 57, 1388, 10.2967/jnumed.115.166850 Assmus, 2015, Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates, Eur J Pharm Sci, 79, 27, 10.1016/j.ejps.2015.08.014 Auberson, 2016, Ligand specific efficiency (LSE) index for PET tracer optimization, ChemMedChem, 11, 1415, 10.1002/cmdc.201600112 Chernet, 2005, Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples, Life Sci, 78, 340, 10.1016/j.lfs.2005.04.075 Barth, 2014, Identifying novel radiotracers for PET imaging of the brain: application of LC–MS/MS to tracer identification, ACS Chem Neurosci, 5, 1148, 10.1021/cn500072r Mitch, 2011, Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer, J Med Chem, 54, 800, 10.1021/jm200789r Zheng, 2013, Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging, J Nucl Med, 54, 455, 10.2967/jnumed.112.109512 Donohue, 2008, Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpirrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging, J Med Chem, 51, 5833, 10.1021/jm800416m Pedregal, 2012, Development of LC–MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor, J Med Chem, 55, 4955, 10.1021/jm201629q Andrés, 2013, Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors, Bioorg & Med Chem Lett, 23, 785, 10.1016/j.bmcl.2012.11.077 Buijnsters, 2014, Structure-based design of a potent, selective and brain penetrating PDE2 inhibitor with demonstrated target engagement, ACS Med Chem Lett, 5, 1049, 10.1021/ml500262u Andrés-Gil, 2013, Janssen Pharmaceutica NV. 1-Aryl-4-methyl-[1,2,4]triazolo [4,3-a]quinoxaline derivatives as PDE2 inhibitors, PCT Int Appl Jack, 2013, Biomarker modeling of Alzheimer’s disease, Neuron, 80, 1347, 10.1016/j.neuron.2013.12.003 Sperling, 2011, Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 280, 10.1016/j.jalz.2011.03.003 Maccioni, 2010, The revitalized tau hypothesis on Alzheimer’s disease, Arch Med Res, 41, 226, 10.1016/j.arcmed.2010.03.007 Villemagne, 2015, Tau imaging: early progress and future directions, Lancet Neurol, 14, 114, 10.1016/S1474-4422(14)70252-2 Walji, 2016, Discovery of 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinolin-5-amine ([18F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs), J Med Chem, 59, 4778, 10.1021/acs.jmedchem.6b00166 Rombouts, 2017, Discovery of N-(pyridin-4-yl)-1,5-naphthyridin-2-amines as potential tau pathology PET tracers for Alzheimer’s disease, J Med Chem, 60, 1272, 10.1021/acs.jmedchem.6b01173 Gobbi, 2017, Identification of three novel radiotracers for imaging aggregated tau in Alzheimer’s disease with positron emission tomography, J Med Chem, 60, 7350, 10.1021/acs.jmedchem.7b00632 Hostetler, 2016, Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles, J Nucl Med, 57, 1599, 10.2967/jnumed.115.171678 Declercq, 2017, Preclinical evaluation of 18F-JNJ64349311, a novel PET tracer for tau imaging, J Nucl Med, 58, 975, 10.2967/jnumed.116.185199